Compare AbbVie Inc (ABBV) vs Vanguard Ultra Short Bond ETF (VUSB) Price & Performance

ABBV trades at $247.91, up 0.76% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported Q2 2026 EPS of $3.65, beating expectations, and maintains strong profitability with a 71.48% gross margin. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer, reinforcing growth prospects beyond Humira's patent expiry.

Outlook is positive with analyst consensus target of $278.69, though high P/E of 70.05 and debt levels pose valuation and financial risks. Revenue growth driven by Skyrizi and Rinvoq offsets competitive pressures, but patent cliffs in the 2030s require monitoring. The stock offers dividend appeal with a $1.73 payout scheduled for August 2026.

VUSB trades at $49.66, up 0.04% on the day, with a bearish technical signal driven by moving averages and ADX readings. Recent dividends include $0.18 paid on July 6, 2026, and $0.17 scheduled for August 5, 2026. Financial ratios such as P/E and ROE are unavailable in the current data, limiting fundamental assessment.

The outlook is cautious due to bearish technical indicators and incomplete financial data. Risks include interest rate sensitivity, as highlighted by recent Fed commentary, and reliance on short-term bond performance. Investors should await updated financial disclosures for a clearer fundamental picture.